Matinas Biopharma Hl (MTNB)

$0.84 0.02 (2.36%)

18:30 EDT MTNB Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 78.96M

PE Ratio -5.25

EPS -0.16

Volume (Avg. Vol.) 731,354

Day's Range 0.83 - 0.87

52-Week Range 0.49 - 2.49

Dividend & Yield N/A (N/A)

MTNB Stock Predictions, Articles, and Matinas Biopharma Hl News

From InvestorPlace
From the Web

7 Cheap Stocks Under $1 That Deserve A Second Look

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Oct 15, 2020

If you're itching for a little excitement in your investing, these cheap stocks under $1 might be just what you're looking for.

5 Stocks Under $5 With Colossal Growth Prospects

By Maya Sasson, Writer, TipRanks Jan 31, 2020

While some argue you get what you pay for, others say that stocks trading at low levels can represent compelling opportunities.

5 Strong Buy Stocks Under $5 With Massive Upside Potential

By Maya Sasson, Writer, TipRanks Dec 26, 2019

Snapping up strong buy stocks with great long-term growth prospects doesn’t have to cost you your entire savings.

FDA on board with late-stage program for Matinas Bio omega-3 therapy (NYSEMKT:MTNB)

From Seeking Alpha Sep 15, 2020

Matinas BioPharma (MTNB +2.2%) confirms that the FDA agrees with the key steps in its planned Phase 3 program for prescription omega-3 therapy MAT9001 for the potential treatment of patients with severe hypertriglyceridemia (elevated triglycerides).A 12-week clinical trial should launch in H1 2021.

The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO

From Benzinga Sep 15, 2020

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG) Applied Molecular Transport Inc. (NASDAQ: AMTI) Avenue Therapeutics Inc (NASDAQ:...

Matinas BioPharma completes enrollment in study of lead candidate vs. Vascepa (NYSEMKT:MTNB)

From Seeking Alpha Aug 27, 2020

Matinas BioPharma (NYSEMKT:MTNB) has completed enrollment in an open-label 100-subject Phase 2 clinical trial, ENHANCE-IT, comparing the effectiveness of lead candidate MAT9001 to Amarin's (NASDAQ:AMRN) Vascepa (icosapent ethyl) in reducing triglyceride levels and other lipid markers in adults with elevated (150 - 499 mg/dL) triglycerides.Each product is being administered twice per day in 2 g doses.

Matinas BioPharma's MAT2203 Phase 1 data published in microbiology journal (NYSEMKT:MTNB)

From Seeking Alpha Aug 20, 2020

Matinas BioPharma (MTNB +1.0%) has announced online publication of data from Phase 1 portion of the EnACT study for MAT2203, in Antimicrobial Agents and Chemotherapy, a journal of the American Society of Microbiology.Phase 1 trial demonstrated that MAT2203 was well tolerated when given in 4-6 divided daily doses without the toxicities commonly seen with IV amphotericin B.

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Lags Revenue Estimates

From Zacks Investment Research Aug 10, 2020

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Looking For Cheap Penny Stocks To Buy? 4 Trading Under $2 Right Now

From PennyStocks.com Aug 6, 2020

Penny Stocks Are 'Cheap' But Are They The Best Option For You?

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy